France’s Sanofi and Britain’s GlaxoSmithKline launched a late-stage human trial for a recombinant COVID-19 vaccine candidate on Thursday which they hope to get approved by the end of 2021.
The study initiated by Sanofi and GSK is one of the first late stage trials that combines tests for boosters and variants, as drugmakers adapt their strategies to deal with an evolving coronavirus.
Read the latest updates in our dedicated coronavirus section.
The two drugmakers, which earlier this month reported positive interim results, confirmed their double-blind, placebo-controlled, phase III study would include more than 35,000 adults in the United States, Asia, Africa, and Latin America.
For the latest headlines, follow our Google News channel online or via the app.
“In a two-stage approach, the study will initially investigate the efficacy of a vaccine formulation targeting the original virus, while a second stage will evaluate a second formulation targeting the B.1.351 virus,” Sanofi said.
The virus lineage known as B.1.351 was first detected in South Africa.
“Recent scientific evidence shows that antibodies created against the B.1.351 variant may provide broad cross-protection against other more transmissible variants,” Sanofi said.
“The design of the Phase III, conducted across a broad diversity of geographies, also allows evaluation of the efficacy of the candidate against a variety of circulating variants,” the French drugmaker added in a statement.
Sanofi also confirmed it would begin clinical studies in the coming weeks to assess the efficacy of the vaccine as a booster, regardless of what vaccine a subject may have received first.
Pending a positive phase III outcome, the vaccine could be approved in the fourth quarter after it was initially targeted for the first half of the year before a setback.
Sanofi and GSK were forced to restart their trial in December when the vaccine showed a low immune response in older adults as a result of a weak antigen formulation.
German researchers find possible cause for rare COVID-19 vaccines blood clot riskGerman researchers on Wednesday said that based on laboratory research, they ... Coronavirus
Belgium suspends J&J COVID-19 vaccine for under 41s after one death caseBelgium said on Wednesday it was suspending vaccinations with Johnson & Johnson’s ... Coronavirus
US FDA may not review new COVID-19 vaccine EUA requests during pandemicThe US Food and Drug Administration said on Tuesday it may decline to review and ... Coronavirus
Vaccines effective against Indian COVID-19 variant: UK officialsBritish health officials expressed optimism Sunday that the coronavirus ... Coronavirus
CureVac works to boost production capacity ahead of expected vaccine approvalGermany’s CureVac expects European approval of its COVID-19 vaccine in June at the ... Coronavirus